Skip to main content
SpringerLink
Log in
Book cover

Bronchuscarcinom pp 23–31Cite as

Experimentelle Therapieansätze

  • Chapter

  • 18 Accesses

Part of the book series: Onkologie heute ((ONKOLOGIE))

Zusammenfassung

Trotz bedeutender Fortschritte auf dem Gebiet der Therapie des Bronchuscarcinoms ist insbesondere die Behandlung der fortgeschrittenen oder rezidivierten Stadien unbefriedigend. Neben Verbesserungen der chirurgischen, radiotherapeutischen und zytostatischen Therapien kommen auch zunehmend biologische Therapien zum Einsatz, die sich jedoch alle derzeit noch in einem experimentellen Stadium befinden. Unser zunehmendes Verständnis über molekularbiologische Grundlagen der Entstehung und des Wachstums von malignen Tumoren hat uns gezeigt, daß ein großer Teil der Bronchuscarcinome mit bestimmten Genveränderungen einhergeht. Im derzeitigen Stadium wird versucht, aus der Analyse solcher molckularbiologischer Marker eine genauere Tumorcharakterisierung und damit eine exaktere Prognose und im Idealfall prädiktiv eine spezifische Therapiestrategie zu erstellen. Die Entwicklung der rekombinanten DNA-Technologie gibt uns jedoch auch die Möglichkeit, direkt in die Regulation dieser Tumorentstehung und -ausbreitung einzugreifen und damit Defekte zu korrigieren oder zu kompensieren. Die Ergebnisse der grundlagenwissenschaftlichen Forschung beginnen nun auch Eingang in die Klinik zu finden. Auch in der Behandlung des Bronchuscarcinoms sind erste Ergebnisse über experimentelle Therapien vorhanden, allerdings ergeben sich daraus noch keine klaren Indikationen. Im folgenden soll in einer kurzen Übersicht auf die Ergebnisse experimenteller Therapieansätze eingegangen werden, wobei allerdings aufgrund der Vielfalt der Möglichkeiten kein Anspruch auf Vollständigkeit erhoben wird.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   29.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   39.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ainslie J, Burdon JG, Henderson MM, Ilbery PL, Matthews JP (1983) The use of levamisole as an adjunct to chemotherapy and radiotherapy in the treatment of small cell carcinoma of the lung. Med J Aust 2(6): 285–287.

    PubMed  CAS  Google Scholar 

  2. Ardizzoni A, Salvati F, Rosso R, Bruzzi P, Rubagotti A, Pennucci MC, Mariani GL, De Marinis F, Pallotta G, Antilli A, et al. (1993) Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multiccntric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force. Cancer 72(10): 2929–2935.

    Article  PubMed  CAS  Google Scholar 

  3. Arnold A, Ayoub J, Douglas L, Hoogendoorn P, Skingley L, Gelmon K, Hirsh V, Eisenhauer E (1994) Phase II trial of 13-cis-retinoic acid plus interferon alpha in nonsmall-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst 86(4): 306–309.

    Article  PubMed  CAS  Google Scholar 

  4. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Vardi Y, Siegel JA, et al. (1997) Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 38(6): 858–870.

    PubMed  CAS  Google Scholar 

  5. Bukowski RM, Murthy S, McLain D, Finke J, Andresen S, Tubbs R, Bauer L, Gibson V, Budd GT, Thomassen MJ (1993) Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: Clinical and immunologic effects. J Immunother 13(4): 267–274.

    Article  CAS  Google Scholar 

  6. Chahinian AP, Goldberg J, Holland JF, Reisman A, Jaffrey IS, Mandel EM (1982) Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterhim parvum in advanced lung cancer. Cancer Treat Rep 66(6): 1291–1297.

    PubMed  CAS  Google Scholar 

  7. Clamon G, Herndon J, Akerley W, Green M (1998) Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: A phase II trial of Cancer and Leukemia Group B. Lung Cancer 19(1): 25–29.

    Article  PubMed  CAS  Google Scholar 

  8. Clamon G, Herndon J, Perry MC, Ozer H, Kreisman H, Maher T, Ellerton J, Green MR (1993) Interleukin-2 activity in patients with extensive small-cell lung cancer: A phase II trial of Cancer and Leukemia Group B. J Natl Cancer Inst 85(4): 316–320.

    Article  PubMed  CAS  Google Scholar 

  9. Decroix G, Chastang C, Fichet D, Asselain B, Lebeau B, Morice V, Lepage T, Babo P, Fabre C, Rebischung JL, et al. (1984) Adjuvant immunotherapy with nonviable Mycobacterium smegmatis in resected primary lung carcinoma. A randomized clinical trial of 219 patients. Cancer 53(4): 906–912.

    Article  PubMed  CAS  Google Scholar 

  10. Dimery IW, Hong WK, Lee JJ, Guillory-Perez C, Pham F, Fritsche Jr. HA, Lippman SM (1997) Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. Ann Oncol 8(1): 85–89.

    Article  PubMed  CAS  Google Scholar 

  11. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA ( 1994) Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86(19): 1458–1462.

    Article  PubMed  CAS  Google Scholar 

  12. Garaci E, Lopez M, Bonsignore G, Delia Giulia M, D’Aprile M, Favalli C, Rasi G, Santini S, Capomolla E, Vici P, et al. (1995) Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer 31A(13-14): 2403–2405.

    Article  PubMed  CAS  Google Scholar 

  13. Genne P, Duchamp O, Solary E, Magnette J, Belon JP, Chauffert B (1995) Cinchonine per os: Efficient circumvention of P-glycoprotein-mediated multidrug resistance. Anticancer Drug Res 10(2): 103–118.

    CAS  Google Scholar 

  14. Gonzalez G, Crombet T, Catala M, Mirabal V, Hernandez JC, Gonzalez Y, Marinello P, Guillen G, Lage A (1998) A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Ann Oncol 9(4): 431–435.

    Article  PubMed  CAS  Google Scholar 

  15. Goodman GE, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D, Hellstrom KE (1990) Phase 1 trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 8(6): 1083–1092.

    PubMed  CAS  Google Scholar 

  16. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266(5192): 1821–1828. ISSN: 0036-8075.

    Article  PubMed  CAS  Google Scholar 

  17. Hollinshead A, Takita H, Stewart T, Raman S (1988) Specific active lung cancer immunotherapy. Immune correlates of clinical responses and an update of immunotherapy trials evaluations. Cancer 62(8): 1662–1671.

    Article  PubMed  CAS  Google Scholar 

  18. Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, Kardinal CG, Twito DI, Levitt R, Gerstner JB (1994) Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 12(11): 2321–2326.

    PubMed  CAS  Google Scholar 

  19. Karasawa K, Muta N, Nakagawa K, Hasezawa K, Terahara A, Onogi Y, Sakata K, Aoki Y, Sasaki Y, Akanuma A (1994) Thermoradiotherapy in the treatment of locally advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 30(5): 1171–1177.

    Article  PubMed  CAS  Google Scholar 

  20. Kelley MJ, Linnoila RI, Avis 1L, Georgiadis MS, Cuttitta F, Mulshine JL, Johnson BE (1997) Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112(1): 256–261.

    Article  PubMed  CAS  Google Scholar 

  21. Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, et al. (1996) Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56(3): 569–573.

    PubMed  CAS  Google Scholar 

  22. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lcmaric E (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules“ Group. Cancer 74(1): 38–45.

    Article  PubMed  CAS  Google Scholar 

  23. Lebeau B, Chastang C, Muir JF, Vincent J, Massin F, Fabre C (1993) No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The “Petites Cellules“ Group. Cancer 71(5): 1741–1745.

    Article  PubMed  CAS  Google Scholar 

  24. Liberati AM, Voelkel JG, Borden EC, Coates AS, Citrin DL, Bryan GT (1982) Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma. Cancer Immunol Immunother 13(2): 140–144.

    Article  PubMed  CAS  Google Scholar 

  25. Maasilta P, Holsti LR, Halme M, Kivisaari L, Cantell K, Mattson K (1992) Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 23(4): 863–868.

    Article  PubMed  CAS  Google Scholar 

  26. Mandanas R, Einhorn LH, Wheeler B, Ansari R, Lutz T, Miller ME (1993) Carboplatin (CBDCA) plus alpha interferon in metastatic non-small cell lung cancer. A Hoosier Oncology Group phase II trial. Am J Clin Oncol 16(6): 519–521.

    Article  PubMed  CAS  Google Scholar 

  27. Mattson K, Niiranen A, Pyrhonen S, Holsti LR, Holsti P, Kumpulainen E, Cantell K (1992) Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer: 1387–1391.

    Google Scholar 

  28. Mehta MP (1998) Protection of normal tissues from the cytotoxic effects of radiation therapy: Focus on amifostine. Semin Radiat Oncol 8(4 Suppl 1): 14–16.

    PubMed  CAS  Google Scholar 

  29. Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R, Engelhardt R (1996) Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer 32A(10): 1712–1718.

    Article  PubMed  CAS  Google Scholar 

  30. Ratto GB, Zino P, Mirabelli S, Minuti P, Aquilina R, Fantino G, Spessa E, Ponte M, Bruzzi P, Melioli G (1996) A randomized trial of adoptive immunotherapy with tumorinfiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma [see comments]. Cancer 78(2): 244–251.

    Article  PubMed  CAS  Google Scholar 

  31. Rinaldi DA, Lippman SM, Burris HAd, Chou C, Von Hoff DD, Hong WK (1993) Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer. Anticancer Drugs 4(1): 33–36.

    Article  PubMed  CAS  Google Scholar 

  32. Robins HI, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Arzoomanian RZ, Alberti D, d’Oleire F, Longo W, Heiss C, et al. (1993) Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthcrmia in cancer patients. J Clin Oncol 11(9): 1787–1794.

    PubMed  CAS  Google Scholar 

  33. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, et al. (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer [sec comments]. Nat Med 2(9): 985–991.

    Article  PubMed  CAS  Google Scholar 

  34. Schiller JH, Storer B, Dreicer R, Rosenquist D, Frontiera M, Carbone PP (1989) Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung. J Natl Cancer Inst 81(22): 1739–1743.

    Article  PubMed  CAS  Google Scholar 

  35. Selvaggi G, Belani CP (1999) Carboplatin and paclitaxel in non-small cell lung cancer: The role of amifostine. Semin Oncol 26(2 Suppl 7): 51–60.

    PubMed  CAS  Google Scholar 

  36. Souter RG, Gill PG, Gunning AJ, Morris PJ (1981) Failure of specific active immunotherapy in lung cancer. Br J Cancer 44(4): 496–501.

    Article  PubMed  CAS  Google Scholar 

  37. Stewart TH, Hollinshead AC, Harris JE, Raman S, Belanger R, Crcpcau A, Crook AF, Hirte WE, Hooper D, Klaassen DJ, et al. (1977) Specific active immunochemotherapy in lung cancer: A survival study. Can J Surg 20(4): 370–377.

    PubMed  CAS  Google Scholar 

  38. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El Naggar AK, Fossella F, Glisson BS, et al. (1999) Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91(9): 763–771.

    Article  PubMed  CAS  Google Scholar 

  39. Tan Y, Xu M, Wang W, Zhang F, Li D, Xu X, Gu J, Hoffman RM (1996) IL-2 gene therapy of advanced lung cancer patients. Anticancer Res 16(4A): 1993–1998.

    PubMed  CAS  Google Scholar 

  40. Tannehill SP, Mehta MP, Larson M, Storer B, Pellet J, Kinsella TJ, Schiller JH (1997) Effect of amifostine ontoxicitics associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: Results of a phase II trial. J Clin Oncol 15(8): 2850–2857.

    PubMed  CAS  Google Scholar 

  41. Thiruvengadam R, Atiba JO, Azawi SH (1996) A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer. Invest New Drugs 14(4): 395–401.

    Article  PubMed  CAS  Google Scholar 

  42. Tummarello D, Graziano F, Isidori P, Santo A, Cetto G, Fedeli A, Rossi G, Cellerino R (1996) Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study. Cancer 77(11): 2251–2257.

    Article  PubMed  CAS  Google Scholar 

  43. Woodruff M, Walbaum P (1983) A phase-II trial of Corynebacterium parvum as adjuvant to surgery in the treatment of operable lung cancer. Cancer Immunol Immunother 16(2): 114–116.

    Article  PubMed  CAS  Google Scholar 

  44. Yang SC, Grimm EA, Parkinson DR, Carinhas J, Fry KD, Mendiguren-Rodriguez A, Licciardello J, Owen-Schaub LB, Hong WK, Roth JA (1991) Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: A phase I trial. Cancer Res 51(14): 3669 3676.

    PubMed  Google Scholar 

  45. Yasumoto K, Ogura T (1991) Intrapleural application of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. A multi-institutional cooperative study. Biotherapy 3(4): 345–349.

    Article  PubMed  CAS  Google Scholar 

  46. Yasumoto K, Yaita H, Ohta M, Azuma I, Nomoto K, Inokuchi K, Yamamura Y (1985) Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative lung cancer patients. Cancer Res 45(3): 1413–1417.

    PubMed  CAS  Google Scholar 

  47. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell Jr. CJ, Forcier RJ, Edwards RL, Headley E, Kim SH, O’Donnell JF, et al. (1984) Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53(10): 2046–2052.

    Article  PubMed  CAS  Google Scholar 

  48. Zarogoulidis K, Ziogas E, Papagiannis A, Charitopoulos K, Dimitriadis K, Economides D, Maglaveras N, Vamvalis C (1996) Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: A randomized trial. Lung Cancer 15(2): 197–205.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Univ.-Klinik für Innere Medizin I, Währinger Gürtel 18-20, A-1090, Wien, Österreich

    Prof. Dr. Christoph Wiltschke & Wolfgang Köstler

Authors
  1. Prof. Dr. Christoph Wiltschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Köstler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph Wiltschke .

Editor information

Editors and Affiliations

  1. Klinische Abteilung für Onkologie, Univ.-Klinik für Innere Medizin I Allgemeines Krankenhaus, Wien, Österreich

    Christoph Zielinski

  2. Klinische Abteilung für Allgemeinchirurgie, Univ.-Klinik für Chirurgie Allgemeines Krankenhaus, Wien, Österreich

    Raimund Jakesz

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Wien

About this chapter

Cite this chapter

Wiltschke, C., Köstler, W. (2000). Experimentelle Therapieansätze. In: Zielinski, C., Jakesz, R. (eds) Bronchuscarcinom. Onkologie heute. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6336-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6336-8_3

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83393-3

  • Online ISBN: 978-3-7091-6336-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation